CELLPROTHERA
CellProthera is the first company having conducted successful proof of principle study with autologous CD34+ stem cells to repair myocardial tissue after acute myocardial infarct (AMI). The clinical outcome indicated an excellent safety profile associated with outstanding clinical benefits. The innovative approach developed by CellProthera is viewed by experts as one of the most effective to treat AMI and prevent secondary congestive heart failure (CHF).
CELLPROTHERA
Industry:
Biotechnology Health Care Medical
Founded:
2008-01-01
Address:
Mulhouse, Alsace, France
Country:
France
Website Url:
http://www.cellprothera.com
Total Employee:
11+
Status:
Active
Contact:
+33369719771
Total Funding:
8.4 M EUR
Technology used in webpage:
Euro IPv6 3 To 9 CcTLD Redirects
Current Employees Featured
Founder
Investors List
Alsace Business Angels
Alsace Business Angels investment in Seed Round - CellProthera
Official Site Inspections
http://www.cellprothera.com Semrush global rank: 7.49 M Semrush visits lastest month: 472
- Host name: cluster007.ovh.net
- IP address: 213.186.33.18
- Location: France
- Latitude: 48.8582
- Longitude: 2.3387
- Timezone: Europe/Paris
More informations about "CellProthera"
CellProthera | Corporate
Didier has more than 30 years of extensive international experience in clinical development, clinical research and medical affairs from various companies, including AstraZeneca and …See details»
CellProthera - Crunchbase Company Profile & Funding
CellProthera is the first company having conducted successful proof of principle study with autologous CD34+ stem cells to repair myocardial tissue after acute myocardial infarct (AMI). …See details»
CellProthera | About
20 years of experience in executive management, corporate strategy, business development and sales, for medtech company and large multinationals.See details»
CellProthera | Pionnier de la Thérapie Régénératrice Cardiaque
Mar 17, 2025 Pour offrir les meilleures expériences, nous utilisons des technologies telles que les cookies pour stocker et/ou accéder aux informations des appareils. Le fait de consentir à …See details»
CellProthera 2025 Company Profile: Valuation, Funding …
Information on valuation, funding, cap tables, investors, and executives for CellProthera. Use the PitchBook Platform to explore the full profile.See details»
CellProthera - Craft
CellProthera has 5 employees across 2 locations. See insights on CellProthera including office locations, competitors, revenue, financials, executives, subsidiaries and more at Craft.See details»
CellProthera - Contacts, Employees, Board Members, Advisors
CellProthera is a medical biotech company based in Mulhouse, France.See details»
CellProthera - VentureRadar
"CellProthera is a medical biotech company founded in 2008 in Mulhouse (France). Its activity is currently focused on the development of a revolutionary therapeutic approach allowing the …See details»
CellProthera | Drug Discovery News
CellProthera begins long-term observational study to demonstrate safety and efficacy of ProtheraCytes® cell therapy in acute myocardial infarction The long-term PERFECT …See details»
CellProthera SAS - Drug pipelines, Patents, Clinical trials - Synapse
Explore CellProthera SAS with its drug pipeline, therapeutic area, technology platform, 4 clinical trials, 11 news, Disease Domain:Nervous System Diseases, Technology …See details»
Interview with CELLPROTHERA, the regenerative …
Apr 2, 2015 Finally, I accepted to help the Hematology and Transplantation Research Institute (IRHT) created and managed by Prof. Philippe Hénon. What can you tell us about CellProthera in a few words? CellProthera is a young …See details»
CellProthera | Pionnier de la Thérapie Régénératrice Cardiaque
Dec 15, 2024 CellProthera was interviewed by France 3 Alsace about the agreement signed with the Japanese hospital Shonan Kamakura.See details»
Company profile | CELLPROTHERA SAS | My Biologics Partner
About us CellProthera has developed an innovative stem cell therapy for the structural and functional regeneration of cardiac lesions following a severe heart attack. This therapy could …See details»
CellProthera - News, Articles, Whitepapers - Drug Target Review
Oct 2, 2024 CellProthera’s Chief Scientific Officer, Ibon Garitaonandia, explains the potential and progress for CGTs in cardiology, where disease-modifying therapies are largely non-existent.See details»
CellProthera inches closer to Phase III trial for heart attack cell …
Aug 30, 2024 Speaking at a press conference, CellProthera’s CEO said the company is moving into the final phase of clinical development for its product.See details»
French biotech CellProthera welcomes three exceptional talents to …
Nov 17, 2021 CellProthera SAS, a clinical stage biotechnology company developing a novel cell therapy for the regeneration of damaged heart tissue and other impairSee details»
A cell therapy to heal a broken heart | Drug Discovery News
CellProthera is currently conducting a clinical trial to reveal whether these variations in their protocol result in more successful clinical translation than previous attempts. Already in the …See details»
CellProthera inks deal for GMP cell therapy manufacturing
Dec 13, 2024 CellProthera announced a deal with SKGH to transfer technology to enable cell therapy manufacturing for clinical trials.See details»
CellProthera | Our people
20 years of experience in executive management, corporate strategy, business development and sales, for medtech company and large multinationals.See details»
Inside the futuristic biotech startup Cellares that’s ... - Fortune
2 days ago The company has now raised $355 million in funding, and signed a $380 million deal last year to reserve manufacturing capacity for Bristol Myers Squibb’s cell therapy drugs. But …See details»